PCV22 AN EVALUATION OF THE CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH SWITCHING HYPERLIPIDEMIC PATIENTS TO PREFERRED STATIN THERAPY IN THE U.S. DEPARTMENT OF DEFENSE  by Omar, MA & Wilson, J
170 Abstracts
PCV22
AN EVALUATION OF THE CLINICAL AND
ECONOMIC OUTCOMES ASSOCIATED WITH
SWITCHING HYPERLIPIDEMIC PATIENTS TO
PREFERRED STATIN THERAPY IN THE U.S.
DEPARTMENT OF DEFENSE
Omar MA ,Wilson J
University of Texas at Austin, Austin,TX, USA
To contain costs associated with lipid-lowering therapy,
the U.S. Department of Defense awarded a contract for
the statin drugs to the manufacturers of cerivastatin and
simvastatin. Hyperlipidemic patients were supposed to be
converted to the preferred statins on or after October 1,
1999.
OBJECTIVES: The primary goal of this study was to
evaluate the clinical and economic outcomes associated
with switching statin therapy of patients from a non-
preferred statin (atorvastatin, ﬂuvastatin, lovastatin or
pravastatin) to a preferred statin (cerivastatin or 
simvastatin). 
METHODS: The study was conducted using retrospec-
tive data from two groups of patients: those for whom
statin prescription records were available (called “Phar-
macy Group”); and a subset of the patients in the 
Pharmacy Group for whom pre- and post-conversion
lipid proﬁles were available (called “Clinical Group”).
RESULTS: For the 181,787 patients in the Pharmacy
Group, the median decrease between pre- and post-
conversion drug cost per patient per month was $5.35.
This translates into a cost avoidance of $11.7 million per
year. Medication compliance of patients in the Pharmacy
Group remained essentially unchanged from pre-
conversion period (0.95) to post-conversion period
(0.97). Out of the 1,552 patients in the Clinical Group
for whom information on National Cholesterol Educa-
tion Program goal status was available, 56.8 percent were
at goal before the switch and 59.1 percent were at goal
after the switch. LDL cholesterol decreased by 5.1
percent, HDL cholesterol increased by 5.8 percent,
triglycerides increased by 2.1 percent, and total choles-
terol decreased by 0.8 percent. 
CONCLUSION: The statin therapy interchange program
resulted in considerable cost savings to the Department
of Defense without clinically important changes in lipid
proﬁles.
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THE EFFECT OF b-BLOCKER AND ACE
INHIBITOR THERAPY ON THE RISK OF
HOSPITALIZATION AND RESOURCE
UTILIZATION AMONG PATIENTS WITH CHF
ENROLLED IN A MANAGED CARE
ORGANIZATION
Abarca J, Malone DC,Armstrong EP
University of Arizona,Tucson, AZ, USA
Pharmacotherapy with ACE inhibitors and b-blockers is
now recommended for most CHF patients and offers the
potential to reduce morbidity and mortality associated
with this disease.
OBJECTIVE: The purpose of this study was to evaluate
the effectiveness of b-blocker and ACE inhibitor therapy
on the risk of hospitalization and total direct medical
expenditures among patients with congestive heart failure
enrolled in a managed care organization (MCO). 
METHODS: Retrospective claims data from an MCO
were analyzed for the 1997–1999 period. Subjects were
included if they had an ICD-9-CM code for CHF and
were continuously eligible for 18 months. Subjects were
categorized by whether they were receiving ACE
inhibitor, ACE inhibitor + b-blocker, or neither (‘no-
therapy’). For each group, an index date was deﬁned
based on the initiation of therapy with an ACE inhibitor
or b-blocker and the initial ICD-9-CM CHF claim. The
effect of each therapy on the risk of all-cause hospital-
ization, CHF-related hospitalization, and total direct
medical costs during the subsequent 12 months following
the index date was analyzed using OLS and logistic
regression models.
RESULTS: A total of 1903 eligible patients were
included. The mean (SD) age was 69.4 ± 12.4 years,
48.8% were male, and the mean (SD) chronic disease
score was 5.89 ± 3.78. ACE inhibitor therapy, but not 
b-blocker therapy, were associated with a signiﬁcant
decrease (34.7 percent, p < 0.0001) in the risk of all-cause
hospitalization. Neither therapy was associated with a
statistically signiﬁcant effect on the risk of CHF-related
hospitalization. ACE inhibitor and b-blocker therapies
was associated with $2064 and $1185 lower total direct
medical costs compared to the ‘no-therapy’ cohort (p <
0.001 for both).
CONCLUSIONS: These results are similar to those of
randomized trials demonstrating the beneﬁts of ACE
inhibitor. The ﬁndings for b-blocker therapies were
mixed, potentially due to confounding by indication.
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APPLICATION OF THE COST OF OBESITY
MODEL FOR COST BENEFIT ANALYSIS (CBA)
OF SIBUTRAMINE AND ORLISTAT:A THIRD
PARTY PAYER’S PERSPECTIVE
Sankaranarayanan J,Viswanathan HN, Bharmal M, Shah B,
Murawski MM
Purdue University, West Lafayette, IN, USA
Sibutramine and orlistat are effective in obesity (a major
independent risk factor for several diseases). High obesity
prevalence, questionable long-term beneﬁts, and drug
costs create a dilemma for insurers on these drug-
coverage decisions.
OBJECTIVE: To determine whether sibutramine or 
orlistat is cost-beneﬁcial in obesity treatment. 
METHODS: Randomized placebo-controlled trials 
evaluating sibutramine or orlistat for weight-loss were
collected from MEDLINE and IPA searches. Inclusion cri-
teria were patients 18 years and older with BMI 27–44
kg/m2. Exclusion criterion was comorbidities. After
